Rexahn Pharmaceuticals (NASDAQ:REXN) is up 19% premarket following its announcement to explore and evaluate strategic alternatives, aimed at boosting shareholder value, including merger, business combination or in-licensing.
The Company has reduced its staff by two positions. REXN anticipates having five employees as of October 1, 2019 and is projecting a year-end 2019 cash and equivalents between $10M and $12M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.